UK – NICE nod for Novartis’ Luxturna

The National Institute for Health and Care Excellence (NICE) has recommended the use of Luxturna (voretigene neparvovec) on the NHS, Novartis has announced.

The treatment has been approved as an option for treating RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations, who have sufficient viable retinal cells

The drug is injected under the retina and carries a functioning RPE65 gene to act in place of the faulty one, and is recommended based on data from a Phase I clinical trial which found that the difference in mean change in binocular MLMT score between patients treated and the control group was 1.6…